Dr. Melissa Brosanders, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: Junction Navajo Route 9, Highway 371, Crownpoint, NM 87313 Phone: 505-786-5291 Fax: 505-786-6440 |
Dr. Daryll Brosanders, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: Junction Navajo Route 9, Highway 371, Crownpoint, NM 87313 Phone: 505-786-5291 |
Dr. John J Johnson, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: Junction Navajo Route 9, Highway 371, Crownpoint, NM 87313 Phone: 505-786-5291 Fax: 505-786-6440 |
Dr. Carla J Sand, M.D Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3 Navarre Blvd, Thoreau Clinic, Crownpoint, NM 87313 Phone: 505-786-5291 Fax: 505-786-6440 |
Dr. David Josephs, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: Junction Navajo Route 9, Highway 371, Crownpoint, NM 87313 Phone: 505-786-5291 Fax: 505-786-6440 |
Ms. Diane E Alaimo, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: Junction Navajo Route 9, Highway 371, Crownpoint, NM 87313 Phone: 505-786-5291 Fax: 505-786-6440 |
News Archive
Lundbeck Inc. ("Lundbeck"), a wholly owned subsidiary of H. Lundbeck A/S in Denmark (Copenhagen: LUN), announced today that the U.S. Food and Drug Administration (FDA) has granted two New Drug Application (NDA) approvals for SabrilĀ® (vigabatrin) Tablets and Oral Solution. Lundbeck plans to launch Sabril in the United States in the third quarter.
In corporation with peers from the Mount Sinai School of Medicine, New York University, researchers from the University of Science and Technology of China (USTC), a CAS affiliate, have come up with new chemical inhibitors against HIV reproduction, marking a significant progress in the development of anti-AIDS drugs based on natural host resistance.
Biocompatible nanocapsules, loaded with an amino acid and equipped with an enzyme now combine two anti-tumor strategies into a synergistic treatment concept. Researchers hope this increases effectiveness and decreases side effects.
Patients with cancer should receive a tailored exercise prescription to protect their heart, reports a paper published today in the European Journal of Preventive Cardiology, a journal of the European Society of Cardiology.
Results of a new study in non-small cell lung cancer showed that patients with specific oncogenic rearrangements of the anaplastic lymphoma kinase (ALK) gene within the short arm of chromosome 2 of their tumors had a much greater response to a new therapy - an ALK-inhibitor.
› Verified 9 days ago